Remimazolam versus propofol for postoperative ICU sedation in mechanically ventilated cancer patients: a noninferiority randomized clinical trial
Frontiers in Pharmacology · 31.03.2026 · 17
DOI: 10.3389/fphar.2026.1784928 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 31.03.2026. Verfasst von Congcong Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Unit, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebei Province Medical Science Research Key Project.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
This study aimed to compare the efficacy and safety of the novel ultra-short-acting benzodiazepine, remimazolam, versus propofol for short-term sedation in postoperative cancer patients during mechanical ventilation in the ICU.
Methods
This single-center, randomized noninferiority clinical trial was conducted from February 1st to 31 August 2024. Adult postoperative cancer patients requiring mechanical ventilation in the ICU were randomized to receive either remimazolam or propofol. The primary outcomes were the time to achieve target sedation (Richmond Agitation-Sedation Scale, RASS, −2 to 0) and the percentage of time within the target range without rescue sedation.
Results
A total of 80 patients were enrolled and randomly assigned to the remimazolam group (n = 40) or the propofol group (n = 40). The time to achieve target sedation was comparable between the remimazolam and propofol groups [median 3.0 (IQR 2.0–4.0) vs. 3.0 (IQR 2.0–4.5) minutes, P = 0.590]. The median percentage of time within the target sedation range was also similar (80.0% vs. 73.2%, P = 0.546). However, remimazolam demonstrated a superior safety profile, with significantly lower incidences of hypotension (15.0% vs. 42.5%, P = 0.007) and respiratory depression (5.0% vs. 20.0%, P = 0.043). No significant differences were observed in secondary outcomes, including duration of mechanical ventilation, ICU length of stay, mortality, or costs.
Conclusion
In mechanically ventilated, postoperative cancer patients, remimazolam provides non-inferior sedation efficacy compared to propofol, but with a significantly more favorable safety profile, particularly regarding hemodynamic and respiratory stability. These findings position Remimazolam as a promising and safer alternative for sedation in this vulnerable population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Intensive Care Unit, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Postgraduate of Intensive Care Unit, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of Intensive Care Unit, The Third Hospital of Shijiazhuang, Shijiazhuang, China.
- Hebei Key Laboratory of Critical Disease Mechanism and Intervention, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Förderung
- Hebei Province Medical Science Research Key Project
Zitieren
APA
Zhao, C., Fan, X., Li, L., Nan, Z., Lin, X., Han, Y., Wu, Y., Yin, Y., Xin, Y., & Hu, Z. (2026). Remimazolam versus propofol for postoperative ICU sedation in mechanically ventilated cancer patients: a noninferiority randomized clinical trial. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1784928
Vancouver
Zhao C, Fan X, Li L, Nan Z, Lin X, Han Y, et al. Remimazolam versus propofol for postoperative ICU sedation in mechanically ventilated cancer patients: a noninferiority randomized clinical trial. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1784928
BibTeX
@article{Zhao2026,
author = {Zhao, Congcong and Fan, Xiaoxuan and Li, Leying and Nan, Zihan and Lin, Xin and Han, Yaqi and Wu, Yanshuo and Yin, Yanling and Xin, Yan and Hu, Zhenjie},
title = {Remimazolam versus propofol for postoperative ICU sedation in mechanically ventilated cancer patients: a noninferiority randomized clinical trial},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1784928}
}
EUVIMED